Commentary: Clinical diagnostic use of cystatin C
β Scribed by Davis Massey
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 84 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0887-8013
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Clinicians recognize and compensate for limitations in estimating the glomerular filtration rate (GFR) using serum creatinine (sCr) measurements by the use of timed collections and mathematical manipulations of sCr. These limitations stem from that fact that sCr is affected by nonrenal influences, including muscle mass and disease state. In addition, sCr may not be sensitive enough to detect minimal declines in GFR in those patient populations in which it is important to recognize early decline. This brief review describes the limitations of sCr, and examines the contribution that sCysC may be able to make in the early recognition of declining renal function. The physiology of CysC is presented, as are the results of clinical investigations that suggest sCysC is in many instances superior to sCr in the recognition of early decline in renal function. Certain exceptions to this are noted. J. Clin. Lab. Anal. 18:55β60, 2004. Β© 2004 WileyβLiss, Inc.
π SIMILAR VOLUMES
## Abstract The use of markerβpeptides, measured by LCβMS/MS, is investigated for the quantitative analysis of proteins. To that end, cystatin C is chosen as a model protein. It not only functions as a proof of concept protein but the growing interest in cystatin C as a new marker of kidney failure
## Abstract The search for whether endogenous markers of changes in glomerular filtration rate (GFR) by serum cystatin C assay and serum cystatin C compare with creatinine clearance by the CockeroftβGault formula and the evaluation of its clinical significance as a marker of GFR is important in cli